RxNorm 1657195

nivolumab 100 MG in 10 ML Injection

RxNorm Semantic Concepts

RxNorm semantic concepts for the RxCUI 1657195 unique identifier include: nivolumab 100 MG in 10 ML Injection (7251175), nivolumab 100 MG per 10 ML Injection (7251174) and 10 ML nivolumab 10 MG/ML Injection (7251170).

RxNorm Atom ID: 7251175 - Prescribable Name
nivolumab 100 MG in 10 ML Injection

RXCUI:
1657195 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
7251175 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
nivolumab 100 MG in 10 ML Injection - Description of concept identifier
Term Type (TTY):
PSN - Term type in source with name and description
Term Type Name:
Prescribable Name - Name of term type in source
Term Type Description:
Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept. - Description of term type in source
Code:
1657195 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom ID: 7251174 - Synonym
nivolumab 100 MG per 10 ML Injection

RXCUI:
1657195 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
7251174 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
nivolumab 100 MG per 10 ML Injection - Description of concept identifier
Term Type (TTY):
SY - Term type in source with name and description
Term Type Name:
Synonym - Name of term type in source
Term Type Description:
Synonym of another TTY, given for clarity. - Description of term type in source
Code:
1657195 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom ID: 7251170 - Semantic Clinical Drug
10 ML nivolumab 10 MG/ML Injection

RXCUI:
1657195 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
7251170 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
10 ML nivolumab 10 MG/ML Injection - Description of concept identifier
Term Type (TTY):
SCD - Term type in source with name and description
Term Type Name:
Semantic Clinical Drug - Name of term type in source
Term Type Description:
Ingredient + Strength + Dose Form - Description of term type in source
Code:
1657195 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom 7251170 Attributes

PropertyValueExplanation
RXN AI{1597877} 1597876RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM{1597877} 1597876RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH10 MG/MLAvailable drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM{1597877} AISource of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUGUSDrug available for use in Humans
RXN QUANTITY10 MLNormal Form quantity factor

* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Patient Education

Nivolumab Injection


Nivolumab injection is used: alone or in combination with ipilimumab (Yervoy) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery, to treat and prevent the return of a certain type of melanoma after surgery to remove it and any affected tissue and lymph nodes, in combination with ipilimumab (Yervoy) to treat a certain type of lung cancer (non-small cell lung cancer; NSCLC) that has spread to other parts of the body, in combination with ipilimumab (Yervoy) and platinum chemotherapy to treat a certain type of NSCLC that has returned or has spread to other parts of the body, alone to treat a certain type of NSCLC that has spread to other parts of the body and has worsened either during or after treatment with platinum chemotherapy medications, to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys) that worsened after treatment with other chemotherapy medications, in combination with ipilimumab (Yervoy) or with cabozantinib (Cabometryx, Cometriq) to treat advanced RCC in people who have not been treated with other chemotherapy medications, to treat Hodgkin's lymphoma (Hodgkin's disease) in adults who worsened or did not respond to autologous stem cell transplant (procedure in which certain blood cells are removed from the body and then returned to the body after chemotherapy and/or radiation treatment) and brentuximab vedotin (Adcetris) treatment or at least three other treatments including the stem cell transplant, to treat a certain type of head and neck cancer that keeps coming back or that has spread to other parts of the body or worsened during or after treatment with other chemotherapy medications, to treat urothelial cancer (cancer of the lining of the bladder and other parts of the urinary tract) that has spread to other parts of the body and has worsened during or after treatment with other chemotherapy medications, alone or in combination with ipilimumab to treat a certain type of colorectal cancer (cancer that begins in the large intestine) in adults and children 12 years of age and older that has spread to other parts of the body and has worsened after treatment with other chemotherapy medications, alone or in combination with ipilimumab to treat hepatocellular carcinoma (HCC; a type of liver cancer) in people who were previously treated with sorafenib (Nexafar), to treat a certain type of esophageal cancer (cancer of the tube that connects your throat to your stomach) that has spread to other parts of the body, has worsened after treatment with other chemotherapy medications, or cannot be treated with surgery. It can also be used in combination with fluorouracil and a platinum-containing chemotherapy medication (cisplatin, carboplatin) to treat another type of esophageal cancer that keeps coming back or has spread to other parts of the body, in combination with fluorouracil and a platinum-containing chemotherapy medication (cisplatin, carboplatin) to treat certain types of gastric cancer (cancer of the stomach) or gastroesophageal junction cancer (cancer located in the area where the stomach meets the esophagus) that has spread to other parts of the body, and in combination with ipilimumab to treat malignant pleural mesothelioma (a type of cancer that affects the inside lining of the lungs and chest cavity) in adults that cannot be removed by surgery. Nivolumab is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells.
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.